Female Infertility Global Market Report 2025

Description

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to sustain a pregnancy. It is a multifactorial condition that results from various factors affecting the reproductive system.

The main treatments for female infertility include clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine. Clomiphene citrate is commonly prescribed to stimulate ovulation in women with infertility. It can be administered in various forms, such as oral, parenteral, and others, and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The female infertility market research report is one of a series of new reports from The Business Research Company that provides female infertility market statistics, including female infertility industry global market size, regional shares, competitors with a female infertility market share, detailed female infertility market segments, market trends and opportunities, and any further data you may need to thrive in the female infertility industry. This female infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The female infertility market size has grown steadily in recent years. It will grow from $1.79 billion in 2024 to $1.86 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to growing trend of women delaying childbirth, increasing changes in lifestyle, increasing government initiatives, rising aging population, increasing assisted reproductive technology (ART) treatment.

The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.18 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to rising awareness of fertility issues, increasing cases of polycystic ovary syndrome, rising cases of uterine abnormalities, rising incidence of genetic disorders, increasing obesity. Major trends in the forecast period include advancements in preimplantation genetic testing, technological advancement, novel technologies for diagnosis, fertility preservation, and telemedicine.

The forecast of 4.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to advanced hysteroscopy equipment and ovulation induction drugs imported from Germany and Israel, potentially prolonging conception timelines and increasing reproductive endocrinology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of infertility is expected to fuel the expansion of the female infertility market in the coming years. Infertility is defined as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The rise in infertility is influenced by factors such as delayed childbearing, lifestyle changes, environmental toxins, increasing obesity rates, and higher stress levels. Treatment for female infertility is necessary to address and manage the underlying medical, hormonal, or structural issues that hinder fertility, improving the chances of conception and preventing permanent infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a UK-based public body under the Department of Health and Social Care, reported that licensed fertility clinics in the UK conducted nearly 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. More than 90% of these patients received treatment with a partner, involving around 100,000 individuals. As a result, the rising prevalence of infertility is driving the growth of the female infertility market.

Key companies in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive advantage. A non-invasive diagnostic test is a medical examination that detects conditions or diseases without the need for surgery or penetration of the body. For example, in August 2024, Heranova Lifesciences, a biotech company based in the US, introduced an early access program for HerResolve, a non-invasive diagnostic test designed for endometriosis. Endometriosis affects around 200 million women globally, causing symptoms such as infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7 to 10 years from the onset of symptoms, largely due to the diverse nature of symptoms and the invasive procedure required for the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve has the potential to reduce this diagnostic delay from years to months, improving patient and healthcare outcomes. The goal of HerResolve is to significantly shorten this timeline, enhancing patient care and results.

In April 2023, CCRM Fertility, a network of fertility clinics based in the US, acquired the New Hope Center for Reproductive Medicine for an undisclosed amount. This acquisition allows CCRM to expand its fertility services on the East Coast, providing greater access to high-quality fertility care, advanced testing, state-of-the-art laboratories, and in-house genetics and research, all contributing to leading success rates. The New Hope Center for Reproductive Medicine, also based in the US, is a fertility clinic offering a variety of services, including in vitro fertilization (IVF) to address female infertility.

Major players in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd.

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in female infertility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the female infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The female infertility market consists of revenues earned by entities by providing services such as hormonal therapy and treatment, genetic testing and counseling, ovulation induction, egg and sperm donation and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. The female infertility market also includes sales of fertility drugs, ovulation test kits, fertility supplements, insemination devices and ultrasound machines for fertility monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Female Infertility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on female infertility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for female infertility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The female infertility market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: Clomiphene Citrate; Gonadotropins; Metformin; Letrozole; Bromocriptine
2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
3) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Clomiphene Citrate: Oral Clomiphene Citrate; Injectable Clomiphene Citrate
2) By Gonadotropins: Recombinant Gonadotropins; Urinary Gonadotropins; Human Chorionic Gonadotropin (hCG)
3) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
4) By Letrozole: Oral Letrozole Tablets; Injectable Letrozole
5) By Bromocriptine: Oral Bromocriptine Tablets; Intranasal Bromocriptine
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck And Co. Inc; Bayer AG; Sanofi S.A.; AstraZeneca Plc; Abbott Laboratories; Mayo Clinic; Teva Pharmaceutical Industries Ltd; Commonwealth Serum Laboratories Ltd; Organon Theramex; Juniper Reproductive Health Ltd.; Sumitomo Pharma; Ferring Pharmaceuticals; Livzon Pharmaceutical Group Co.; Mankind Pharma; Kissei Pharmaceutical Co Ltd; ASKA Pharmaceutical Co. Ltd.; Fuji Pharma Co. Ltd.; ARMC IVF; Zydus Cadila Healthcare; IBSA Institut Biochimique; Oxolife; Ava AG; Hernova Lifesciences Holdings Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r33717u

1. Executive Summary

2. Female Infertility Market Characteristics

3. Female Infertility Market Trends And Strategies

4. Female Infertility Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Female Infertility Growth Analysis And Strategic Analysis Framework

5.1. Global Female Infertility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Female Infertility Market Growth Rate Analysis
5.4. Global Female Infertility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Female Infertility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Female Infertility Total Addressable Market (TAM)

6. Female Infertility Market Segmentation

6.1. Global Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clomiphene Citrate
Gonadotropins
Metformin
Letrozole
Bromocriptine
6.2. Global Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Route Of Administrations
6.3. Global Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Female Infertility Market, Sub-Segmentation Of Clomiphene Citrate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Clomiphene Citrate
Injectable Clomiphene Citrate
6.5. Global Female Infertility Market, Sub-Segmentation Of Gonadotropins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Gonadotropins
Urinary Gonadotropins
Human Chorionic Gonadotropin (hCG)
6.6. Global Female Infertility Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate-Release Metformin
Extended-Release Metformin
6.7. Global Female Infertility Market, Sub-Segmentation Of Letrozole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Letrozole Tablets
Injectable Letrozole
6.8. Global Female Infertility Market, Sub-Segmentation Of Bromocriptine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Bromocriptine Tablets
Intranasal Bromocriptine

7. Female Infertility Market Regional And Country Analysis

7.1. Global Female Infertility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Female Infertility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Female Infertility Market

8.1. Asia-Pacific Female Infertility Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Female Infertility Market

9.1. China Female Infertility Market Overview
9.2. China Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Female Infertility Market

10.1. India Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Female Infertility Market

11.1. Japan Female Infertility Market Overview
11.2. Japan Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Female Infertility Market

12.1. Australia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Female Infertility Market

13.1. Indonesia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Female Infertility Market

14.1. South Korea Female Infertility Market Overview
14.2. South Korea Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Female Infertility Market

15.1. Western Europe Female Infertility Market Overview
15.2. Western Europe Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Female Infertility Market

16.1. UK Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Female Infertility Market

17.1. Germany Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Female Infertility Market

18.1. France Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Female Infertility Market

19.1. Italy Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Female Infertility Market

20.1. Spain Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Female Infertility Market

21.1. Eastern Europe Female Infertility Market Overview
21.2. Eastern Europe Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Female Infertility Market

22.1. Russia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Female Infertility Market

23.1. North America Female Infertility Market Overview
23.2. North America Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Female Infertility Market

24.1. USA Female Infertility Market Overview
24.2. USA Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Female Infertility Market

25.1. Canada Female Infertility Market Overview
25.2. Canada Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Female Infertility Market

26.1. South America Female Infertility Market Overview
26.2. South America Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Female Infertility Market

27.1. Brazil Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Female Infertility Market

28.1. Middle East Female Infertility Market Overview
28.2. Middle East Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Female Infertility Market

29.1. Africa Female Infertility Market Overview
29.2. Africa Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Female Infertility Market Competitive Landscape And Company Profiles

30.1. Female Infertility Market Competitive Landscape
30.2. Female Infertility Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Female Infertility Market Other Major And Innovative Companies

31.1. AstraZeneca Plc
31.2. Abbott Laboratories
31.3. Mayo Clinic
31.4. Teva Pharmaceutical Industries Ltd
31.5. Commonwealth Serum Laboratories Ltd
31.6. Organon Theramex
31.7. Juniper Reproductive Health Ltd.
31.8. Sumitomo Pharma
31.9. Ferring Pharmaceuticals
31.10. Livzon Pharmaceutical Group Co.
31.11. Mankind Pharma
31.12. Kissei Pharmaceutical Co Ltd
31.13. ASKA Pharmaceutical Co. Ltd.
31.14. Fuji Pharma Co. Ltd.
31.15. ARMC IVF

32. Global Female Infertility Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Female Infertility Market

34. Recent Developments In The Female Infertility Market

35. Female Infertility Market High Potential Countries, Segments and Strategies

35.1 Female Infertility Market In 2029 - Countries Offering Most New Opportunities
35.2 Female Infertility Market In 2029 - Segments Offering Most New Opportunities
35.3 Female Infertility Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer